Jinhe Historical Income Statement

002688 Stock

4.52 0.04 0.89%

Historical analysis of Jinhe Biotechnology income statement accounts such as Selling General Administrative of 167.5 M, Total Revenue of 1.5 B or Operating Income of 167.7 M can show how well Jinhe Biotechnology Co performed in making a profits. Evaluating Jinhe Biotechnology income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Jinhe Biotechnology's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Jinhe Biotechnology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Jinhe Biotechnology is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

About Jinhe Income Statement Analysis

Jinhe Biotechnology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Jinhe Biotechnology shareholders. The income statement also shows Jinhe investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Jinhe Biotechnology Income Statement Chart

At present, Jinhe Biotechnology's Selling General Administrative is projected to increase significantly based on the last few years of reporting. The current year's Income Before Tax is expected to grow to about 139.9 M, whereas Interest Expense is forecasted to decline to about 8.6 M.

Total Revenue Operating Income Cost Of Revenue

Total Revenue

Total revenue comprises all receipts Jinhe Biotechnology generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Operating Income

Operating Income is the amount of profit realized from Jinhe Biotechnology operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Jinhe Biotechnology Co is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.

Cost Of Revenue

Cost of Revenue is found on Jinhe Biotechnology income statement and represents the costs associated with goods and services Jinhe Biotechnology provides. Indirect cost, such as salaries, is not included. In other words, cost of revenue is the total cost incurred to obtain a sale. It is more than the traditional cost of goods sold, since it includes specific selling and marketing activities.

Most accounts from Jinhe Biotechnology's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Jinhe Biotechnology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Jinhe Biotechnology Co. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

	2021	2022	2023	2024 (projected)
Operating Income	230.9M	172.0M	187.7M	167.7M
Total Revenue	2.1B	2.1B	2.2B	1.5B

Operating Income Total Revenue

Jinhe Biotechnology income statement Correlations

	Selling General Administrative	Total Revenue	Operating Income	Cost Of Revenue	Income Before Tax	Net Income	Income Tax Expense	Minority Interest	Research Development	Gross Profit	Other Operating Expenses	Net Income From Continuing Ops	Ebit	Total Operating Expenses	Total Other Income Expense Net	Tax Provision	Net Interest Income	Interest Income	Ebitda	Reconciled Depreciation
Selling General Administrative		0.77	0.77	0.75	0.64	0.58	0.08	0.25	0.68	0.65	-0.24	0.24	0.33	0.54	0.34	-0.49	-0.3	0.24	0.56	0.44
Total Revenue	0.77		0.88	0.99	0.53	0.43	-0.04	0.18	0.9	0.91	-0.48	0.21	0.48	0.88	0.62	-0.76	-0.21	0.46	0.76	0.79
Operating Income	0.77	0.88		0.83	0.74	0.66	0.25	0.49	0.7	0.87	-0.16	0.4	0.7	0.65	0.42	-0.57	-0.35	0.41	0.62	0.51
Cost Of Revenue	0.75	0.99	0.83		0.46	0.35	-0.12	0.09	0.91	0.86	-0.54	0.14	0.41	0.9	0.65	-0.77	-0.15	0.46	0.74	0.83
Income Before Tax	0.64	0.53	0.74	0.46		0.97	0.65	0.66	0.24	0.58	0.27	0.81	0.86	0.2	0.15	-0.09	-0.39	0.04	0.4	0.01
Net Income	0.58	0.43	0.66	0.35	0.97		0.62	0.73	0.16	0.5	0.32	0.83	0.8	0.11	0.11	-0.03	-0.34	0.08	0.4	-0.05
Income Tax Expense	0.08	-0.04	0.25	-0.12	0.65	0.62		0.55	-0.38	0.0	0.76	0.6	0.66	-0.39	-0.54	0.6	-0.41	-0.57	-0.25	-0.56
Minority Interest	0.25	0.18	0.49	0.09	0.66	0.73	0.55		-0.01	0.32	0.53	0.7	0.7	-0.16	-0.2	0.07	-0.46	0.13	0.13	-0.28
Research Development	0.68	0.9	0.7	0.91	0.24	0.16	-0.38	-0.01		0.85	-0.67	0.0	0.17	0.94	0.75	-0.89	-0.17	0.58	0.83	0.89
Gross Profit	0.65	0.91	0.87	0.86	0.58	0.5	0.0	0.32	0.85		-0.44	0.31	0.57	0.85	0.61	-0.77	-0.19	0.56	0.86	0.73
Other Operating Expenses	-0.24	-0.48	-0.16	-0.54	0.27	0.32	0.76	0.53	-0.67	-0.44		0.52	0.32	-0.78	-0.7	0.82	-0.5	-0.65	-0.55	-0.88
Net Income From Continuing Ops	0.24	0.21	0.4	0.14	0.81	0.83	0.6	0.7	0.0	0.31	0.52		0.8	-0.05	0.09	0.13	-0.58	-0.15	0.25	-0.23
Ebit	0.33	0.48	0.7	0.41	0.86	0.8	0.66	0.7	0.17	0.57	0.32	0.8		0.2	0.12	-0.08	-0.42	0.04	0.26	-0.01
Total Operating Expenses	0.54	0.88	0.65	0.9	0.2	0.11	-0.39	-0.16	0.94	0.85	-0.78	-0.05	0.2		0.81	-0.9	0.03	0.59	0.83	0.97
Total Other Income Expense Net	0.34	0.62	0.42	0.65	0.15	0.11	-0.54	-0.2	0.75	0.61	-0.7	0.09	0.12	0.81		-0.79	0.1	0.68	0.78	0.81
Tax Provision	-0.49	-0.76	-0.57	-0.77	-0.09	-0.03	0.6	0.07	-0.89	-0.77	0.82	0.13	-0.08	-0.9	-0.79		-0.07	-0.78	-0.75	-0.91
Net Interest Income	-0.3	-0.21	-0.35	-0.15	-0.39	-0.34	-0.41	-0.46	-0.17	-0.19	-0.5	-0.58	-0.42	0.03	0.1	-0.07		0.39	-0.02	0.21
Interest Income	0.24	0.46	0.41	0.46	0.04	0.08	-0.57	0.13	0.58	0.56	-0.65	-0.15	0.04	0.59	0.68	-0.78	0.39		0.64	0.67
Ebitda	0.56	0.76	0.62	0.74	0.4	0.4	-0.25	0.13	0.83	0.86	-0.55	0.25	0.26	0.83	0.78	-0.75	-0.02	0.64		0.78
Reconciled Depreciation	0.44	0.79	0.51	0.83	0.01	-0.05	-0.56	-0.28	0.89	0.73	-0.88	-0.23	-0.01	0.97	0.81	-0.91	0.21	0.67	0.78

Click cells to compare fundamentals

Jinhe Biotechnology Account Relationship Matchups

Jinhe Biotechnology income statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Interest Expense	61.3M	60.3M	56.3M	46.6M	9.1M	8.6M
Selling General Administrative	182.1M	172.5M	179.8M	188.5M	162.5M	167.5M
Total Revenue	1.8B	1.8B	2.1B	2.1B	2.2B	1.5B
Operating Income	199.2M	231.3M	230.9M	172.0M	187.7M	167.7M
Cost Of Revenue	1.1B	1.2B	1.4B	1.5B	1.5B	967.2M
Income Before Tax	220.2M	140.9M	142.9M	118.8M	101.5M	139.9M
Net Income Applicable To Common Shares	184.9M	117.3M	94.0M	75.5M	86.9M	112.1M
Net Income	184.9M	117.3M	94.0M	75.5M	86.5M	111.0M
Income Tax Expense	29.9M	1.7M	20.8M	804.3K	924.9K	878.7K
Minority Interest	128.0M	135.1M	(28.1M)	(42.5M)	(8.0M)	(7.6M)
Research Development	60.7M	66.4M	72.3M	82.3M	74.0M	53.7M
Gross Profit	653.1M	629.9M	651.1M	613.8M	642.5M	638.3M
Other Operating Expenses	16.7M	12.3M	12.2M	2.7M	2.4M	2.3M
Net Income From Continuing Ops	190.3M	139.2M	122.1M	118.0M	94.4M	109.2M
Ebit	240.8M	210.9M	203.0M	164.5M	148.0M	168.1M
Total Operating Expenses	1.5B	1.6B	1.8B	2.0B	2.0B	1.7B
Tax Provision	29.9M	1.7M	20.8M	804.3K	7.1M	6.7M
Net Interest Income	(60.7M)	(53.3M)	(56.1M)	(47.6M)	13.9M	14.6M
Interest Income	3.4M	9.5M	1.7M	1.9M	8.4M	8.8M
Ebitda	381.0M	321.2M	331.3M	321.3M	369.5M	356.4M
Reconciled Depreciation	99.4M	120.0M	132.1M	155.9M	179.3M	132.9M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Other Information on Investing in Jinhe Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Jinhe Historical Income Statement

About Jinhe Income Statement Analysis

Jinhe Biotechnology Income Statement Chart

Total Revenue

Operating Income

Cost Of Revenue

Jinhe Biotechnology income statement Correlations

Jinhe Biotechnology Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Jinhe Biotechnology income statement Accounts

Also Currently Popular

Other Information on Investing in Jinhe Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cost Of Revenue	+ 0.99	Total Revenue
Net Income	+ 0.97	Income Before Tax
Reconciled Depreciation	+ 0.97	Total Operating Expenses
Total Operating Expenses	+ 0.94	Research Development
Gross Profit	+ 0.91	Total Revenue
Research Development	+ 0.91	Cost Of Revenue

Reconciled Depreciation	- 0.91	Tax Provision
Tax Provision	- 0.9	Total Operating Expenses
Tax Provision	- 0.89	Research Development
Reconciled Depreciation	- 0.88	Other Operating Expenses
Tax Provision	- 0.79	Total Other Income Expense Net
Interest Income	- 0.78	Tax Provision